Sanofi, the French pharmaceutical giant, has initiated discussions with Clayton Dubilier & Rice, a U.S. private equity firm, regarding the potential sale of a controlling 50% stake in its consumer health division, Opella. This step follows earlier reports from Reuters that suggested the valuation of the sale could reach approximately 15 billion euros, equivalent to...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here